eligibility_summary
Adults 18–75 with progressive R/R multiple myeloma or plasma cell leukemia, measurable disease (M‑protein, sFLC, or ≥2% circulating plasma cells), ECOG 0–1, >12‑week survival, adequate coagulation, renal, hepatic function, contraception required. Exclude: pregnancy/lactation, HIV/syphilis/acute CMV/EBV or active HBV/HCV, uncontrolled infection/illness, unresolved AEs, prior BCMA CAR‑T or allo‑SCT, recent ASCT/therapy/steroids/vaccines, LVEF<50%, O2‑dependence, autoimmune/CNS disease, recent/planned major surgery.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CT0594CP, a dual allogeneic UCAR-T cell therapy combining BCMA-UCAR-T (CT0594) and CD9-UCAR-T (CT7590), type: genetically modified T‑cell (cellular immunotherapy), administered by cell infusion. Mechanism: CAR-engineered T cells recognize BCMA or CD9 on malignant plasma cells, activating T-cell cytotoxicity and cytokine release to kill tumor cells, dual antigen targeting aims to reduce antigen escape. Targets: BCMA+ and/or CD9+ cells in relapsed/refractory multiple myeloma or plasma cell leukemia, pathways centered on BCMA and CD9 surface antigen signaling.